Investors

Kadimastem on Tel-Aviv Stock Exchange

November 17, 2024 at 7:37:23 AM

November 5, 2024 at 7:34:17 AM

October 29, 2024 at 8:05:32 AM

July 29, 2024 at 11:11:06 AM

June 23, 2024 at 7:08:03 AM

February 28, 2024 at 2:10:37 PM

February 14, 2024 at 10:00:00 PM

February 7, 2024 at 10:44:02 AM

January 24, 2024 at 10:00:00 PM

January 22, 2024 at 8:10:35 AM

November 7, 2023 at 7:16:58 AM

June 20, 2023 at 7:32:57 AM

May 15, 2023 at 11:10:42 AM

May 9, 2023 at 6:16:05 AM

March 19, 2023 at 7:43:32 AM

February 19, 2023 at 10:13:44 AM

February 15, 2023 at 10:16:24 AM

February 5, 2023 at 8:15:19 AM

January 9, 2023 at 2:19:09 PM

December 20, 2022 at 9:55:35 AM

September 28, 2022 at 6:47:50 AM

August 9, 2022 at 7:36:45 AM

June 8, 2022 at 6:24:04 AM

May 30, 2022 at 12:56:40 PM

May 17, 2022 at 9:00:00 PM

March 3, 2022 at 1:08:29 PM

December 13, 2021 at 10:36:37 AM

November 29, 2021 at 12:20:17 PM

November 15, 2021 at 6:28:17 AM

October 26, 2021 at 5:52:59 AM

Investors

Investors

For More Investors Info.

Vote of Confidence by Major Kadimastem Shareholder in the Merger Transaction with Swiss Biopharma Company NLS Pharmaceutics

NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement

Kadimastem completes another stage towards the merger with NLS Pharmaceutics, which has Regained Full Compliance with Nasdaq Listing Requirements

Kadimastem Ltd. and NLS Pharmaceutics Announce Binding Term Sheet to Merge

The World Prestigious Diabetes Research Institute, University of Miami, Announces Kadimastem's Joint Project as Breakthrough Transplantation Approach for the Treatment of Type 1 Diabetes

Kadimastem Takes Another Step Towards Signing the Merger Agreement with Nasdaq Listed IMCC

Kadimastem advances towards Nasdaq: Company Signs a Memorandum of Understanding to Merge with a Company traded on the Nasdaq

Kadimastem Receives Patent for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes in India

A peer reviewed article on Kadimastem's AstroRx® Cryopreserved off the Shelf Cell Product for the Treatment of ALS was Published in the Journal of Clinical Toxicology

Kadimastem and iTolerance Complete Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) Meeting with the U.S. FDA

Kadimastem and iTolerance Submit INTERACT Request with FDA for Potential Cure for Type 1 Diabetes

Kadimastem Receives US Patent for Its Cell Selection & Enrichment Technology Used to Develop IsletRx

Kadimastem Granted European Patent for Its IsletRx Treatment for Diabetes

Kadimastem and iTolerance Sign Agreement and Receive US$1 Million from BIRD Foundation

Kadimastem Earns FDA IND Approval For its US Phase IIa Clinical Trial with AstroRx® to Treat ALS

Kadimastem Submits IND Application to the FDA for its Phase IIa Clinical Trial with AstroRx® for ALS

Kadimastem's Clinical Trial in ALS Patients was Publicized in the Journal of Translational Medicine

Awarded Patent in Australia for its AstroRx® Technology for the Treatment of ALS and Drug Screening

Kadimastem Announces it raised appx 7.5 million NIS by rights offering

Kadimastem and iTolerance’s Proposed Collaboration With Receipt of US $1 Million BIRD Grant

Kadimastem Receives Approval of Patent registration Used to Develop IsletRx for Diabetes

Kadimastem Receives US Patent For Amyotrophic Lateral Sclerosis (ALS) Treatment

Kadimastem and Implant Therapeutics, Inc. Sign an Evaluation Agreement

Kadimastem Awarded Patent in Japan for AstroRx® For ALS and Drug Screening

Kadimastem Expands R&D Program to Include Multiple Sclerosis

Kadimastem Receives Grant for a Total Budget of $3.1 million from the Israeli Innovation Authority

Kadimastem Announces the Approval of a 4M NIS ($1.29M) Budget from the Israel Innovation Authority

ILEX Medical to Invest 10 million NIS ($3.2 million)

We rang the TASE bell today!

Kadimastem Raises NIS 16.1 million ($5 million) In Private Placement